Related Experiment Videos
Respiratory syncytial virus infections and intravenous gamma-globulins
V G Hemming1, G A Prince, W Rodriguez
1Department of Pediatrics, F. Edward Hebert College of Medicine, Uniformed Services University of Health Sciences, Bethesda, MD.
Insights
Intravenous immunoglobulin (Sandoglobulin) offers a safe and effective way to prevent and treat respiratory syncytial virus (RSV) infections in both animals and children, reducing viral shedding and improving oxygenation.
Area of Science:
- Virology
- Immunology
- Pediatrics
Background:
- Respiratory syncytial virus (RSV) causes significant infant respiratory illness globally.
- Limited treatment options existed for RSV infections prior to ribavirin.
- Intravenous immunoglobulin (IVIG) demonstrated RSV-neutralizing antibodies.
Purpose of the Study:
- To evaluate the safety and efficacy of Sandoglobulin (a type of IVIG) for RSV.
- To assess Sandoglobulin in both prophylaxis and treatment of RSV infections.
- To investigate Sandoglobulin's use in animal models and human clinical trials.
Main Methods:
- Studies conducted in cotton rat and owl monkey models of RSV infection.
- Parenteral and topical Sandoglobulin administration in animal models.
- A double-blind trial of Sandoglobulin versus albumin in hospitalized children with RSV.
Main Results:
- Sandoglobulin was well-tolerated and safe in animal models, significantly reducing lower respiratory tract RSV shedding.
- Immunotherapy with Sandoglobulin in children was well-tolerated with no observed toxicity.
- Children treated with Sandoglobulin showed improved oxygenation and reduced RSV shedding.
Conclusions:
- Sandoglobulin is a safe and effective option for immunoprophylaxis and immunotherapy of RSV infections.
- IVIG therapy demonstrates significant clinical benefits in treating RSV-related respiratory illness.
- Further research supports the use of IVIG in managing RSV infections in vulnerable populations.
Abstract:
The respiratory syncytial virus (RSV) is a common cause of bronchiolitis and pneumonia in infants and young children. Throughout the world annual RSV epidemics result in numerous hospitalizations, substantial morbidity and some mortality. Until the recent introduction of ribavirin only supportive therapy has been available for treating these infections. The development of animal models of RSV infection and the observation that some lots of immunoglobulin prepared for intravenous administration contained substantial RSV-neutralization antibody titers, prompted a series of studies examining the safety and efficacy of immunoglobulin prepared for intravenous administration in the prophylaxis and treatment of RSV infections. This discussion will review our published, or soon to be published, studies on the use of Sandoglobulin for both immunoprophylaxis and immunotherapy of RSV infections in cotton rats. It will summarize studies utilizing both parenteral and topical (tracheal) Sandoglobulin therapy for RSV infections in owl monkeys. Finally the results of a small double blind trial of parenteral albumin or Sandoglobulin in the therapy of RSV bronchiolitis and/or pneumonia in hospitalized children will be reviewed. The data show that immunoprophylaxis and immunotherapy of RSV infections in laboratory animals was well-tolerated, was safe and induced highly significant reductions in RSV shedding from the lower respiratory tract. Further, immunotherapy of RSV infections in children was also well-tolerated, induced no short or long term evidence of toxicity or injury and caused significant improvements in oxygenation and reductions in RSV shed from the respiratory tract.(ABSTRACT TRUNCATED AT 250 WORDS)